Get the Stockscreener App
3.065
1.99%
0.055
After Hours:
3.06
-0.005
-0.16%
Terns Pharmaceuticals Inc stock is traded at $3.065, with a volume of 451.86K.
It is up +1.99% in the last 24 hours and up +4.42% over the past month.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
See More
Previous Close:
$3.01
Open:
$3.02
24h Volume:
451.86K
Relative Volume:
0.44
Market Cap:
$267.70M
Revenue:
-
Net Income/Loss:
$-95.90M
P/E Ratio:
-2.322
EPS:
-1.32
Net Cash Flow:
$-79.09M
1W Performance:
+2.50%
1M Performance:
+4.42%
6M Performance:
-51.58%
1Y Performance:
-51.42%
1-Day Range:
$2.995
$3.17
1-Week Range:
$2.84
$3.17
52-Week Range:
$1.865
$11.40
Terns Pharmaceuticals Inc Stock (TERN) Company Profile
Name
Terns Pharmaceuticals Inc
Sector
Industry
Phone
650-525-5535 EXT.101
Address
1065 EAST HILLSDALE BLVD., SUITE 100, FOSTER CITY
Compare TERN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TERN
Terns Pharmaceuticals Inc
|
3.065 | 275.11M | 0 | -95.90M | -79.09M | -1.32 |
|
ONC
Beigene Ltd Adr
|
240.41 | 25.61B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.28 | 114.83B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.30 | 41.82M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.43 | 66.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
73.93 | 6.36B | 0 | -153.72M | -103.81M | -2.00 |
Terns Pharmaceuticals Inc Stock (TERN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-28-25 | Initiated | William Blair | Mkt Perform |
| Oct-31-24 | Initiated | Oppenheimer | Outperform |
| Jun-22-23 | Initiated | Mizuho | Buy |
| Jun-07-23 | Initiated | Jefferies | Buy |
| May-31-23 | Initiated | ROTH MKM | Buy |
| May-08-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-14-23 | Initiated | JMP Securities | Mkt Outperform |
| Feb-07-23 | Initiated | UBS | Buy |
| Sep-12-22 | Initiated | H.C. Wainwright | Neutral |
| Sep-14-21 | Resumed | Goldman | Buy |
| Mar-02-21 | Initiated | Cowen | Outperform |
| Mar-02-21 | Initiated | Goldman | Buy |
| Mar-02-21 | Initiated | JP Morgan | Overweight |
View All
Terns Pharmaceuticals Inc Stock (TERN) Latest News
Millennium Management LLC Has $8.92 Million Stock Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
Terns Pharmaceuticals’ SWOT analysis: promising pipeline drives stock potential By Investing.com - Investing.com Nigeria
Nuveen Asset Management LLC Buys 617,009 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
Terns Pharmaceuticals’ SWOT analysis: promising pipeline drives stock potential - Investing.com
Northern Trust Corp Has $3.28 Million Stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
Deutsche Bank AG Has $2.21 Million Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
BNP Paribas Financial Markets Acquires New Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
Cubist Systematic Strategies LLC Decreases Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Shares Sold by The Manufacturers Life Insurance Company - Defense World
BMO Capital Markets Issues Pessimistic Forecast for Terns Pharmaceuticals (NASDAQ:TERN) Stock Price - Defense World
Terns Pharmaceuticals Selected for Oral Presentation at - GlobeNewswire
Terns Pharmaceuticals Selected for Oral Presentation at European - GuruFocus
Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701 - The Manila Times
Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association ... - Bluefield Daily Telegraph
Breakthrough: New Leukemia Drug TERN-701 Outperforms Standard Treatment in Multiple Resistance Cases - Stock Titan
Terns Pharma (TERN) Price Target Lowered by BMO Capital | TERN S - GuruFocus
Pfizer (PFE): Patent Developments Affect Terns Pharmaceuticals | PFE Stock News - GuruFocus
Pfizer (PFE): Patent Developments Affect Terns Pharmaceuticals | - GuruFocus
Terns Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
Dimensional Fund Advisors LP Raises Stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
Hsbc Holdings PLC Grows Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
Is Terns Pharmaceuticals, Inc. (TERN) the Low Risk High Reward Stock Set to Triple by 2030? - Insider Monkey
Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewswire
10 Low Risk High Reward Stocks Set to Triple by 2030 - Insider Monkey
Terns (TERN) Advances Clinical Programs with Promising Developme - GuruFocus
BRIEF-Terns Pharmaceuticals Q1 Net Income USD -23.908 Million - TradingView
Wells Fargo & Company MN Has $227,000 Stock Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
MetLife Investment Management LLC Acquires 9,500 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
JPMorgan Chase & Co. Reduces Stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Terns Pharmaceuticals Reports Inducement Grants to New Employees - GuruFocus
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) | TERN Stock News - GuruFocus
Biotech Firm Terns Awards Massive 325,000 Share Options Package to New Key Hires - Stock Titan
What is Terns Pharmaceuticals Inc (TERN) Stock Return on Shareholders’ Capital? - Sete News
Terns Pharmaceuticals Inc (TERN) deserves deeper analysis - uspostnews.com
Terns Pharmaceuticals to Participate in The Citizens Life Sciences Conference - The Manila Times
Terns Pharma Leaders to Reveal Latest Oncology and Obesity Drug Pipeline Updates at Major Conference - Stock Titan
An Analysis of Terns Pharmaceuticals Inc (TERN)’s Potential Price Growth - knoxdaily.com
Terns Pharmaceuticals Inc’s: Contrasting Stock Performances in a Volatile Market - investchronicle.com
Terns Pharmaceuticals Inc (NASDAQ: TERN) Stock Could Make A -543.09% Loss - Marketing Sentinel
Analyzing Ratios: Terns Pharmaceuticals Inc (TERN)’s Financial Story Unveiled - DWinneX
Market Resilience: Terns Pharmaceuticals Inc (TERN) Finishes Weak at 2.10, Down -9.87 - DWinneX
A Look at Terns Pharmaceuticals Inc (TERN) Shares in the Recent Past Indicates Growth - Sete News
TERN overperforms with a 2.86 increase in share price - uspostnews.com
Geode Capital Management LLC Has $8.40 Million Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
A company insider recently sold 952 shares of Terns Pharmaceuticals Inc [TERN]. Should You also Consider to Sale? - knoxdaily.com
An Analysis Of Terns Pharmaceuticals Inc (TERN) Stock - Marketing Sentinel
We're Not Very Worried About Terns Pharmaceuticals' (NASDAQ:TERN) Cash Burn Rate - Yahoo Finance
TERN’s Stock Market Puzzle: Piecing Together 2023’s Performance - investchronicle.com
Terns Pharmaceuticals (NASDAQ:TERN) Receives Market Outperform Rating from JMP Securities - Defense World
Terns Pharmaceuticals Reports Third Quarter 2024 Financial Results and Corporate Updates - ADVFN
Terns Pharmaceuticals Inc Stock (TERN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Terns Pharmaceuticals Inc Stock (TERN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Jung Melita Sun | Chief Business Officer |
Nov 30 '24 |
Buy |
5.11 |
2,250 |
11,498 |
2,250 |
| Burroughs Amy L. | Chief Executive Officer |
Nov 30 '24 |
Buy |
5.11 |
510 |
2,606 |
19,609 |
| Kuriakose Emil | Chief Medical Officer |
Jan 02 '25 |
Sale |
5.71 |
4,481 |
25,607 |
54,269 |
| Vignola Mark J. | Chief Financial Officer |
Jan 06 '25 |
Sale |
5.80 |
9,059 |
52,500 |
74,752 |
| Vignola Mark J. | Chief Financial Officer |
Jan 02 '25 |
Sale |
5.72 |
8,129 |
46,524 |
83,811 |
| Quigley Jill M. | Director |
Jan 06 '25 |
Sale |
5.79 |
8,760 |
50,758 |
0 |
| Quigley Jill M. | Director |
Jan 02 '25 |
Sale |
5.72 |
6,240 |
35,702 |
8,760 |
0.00%
0.96%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):